Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Addison's disease market prospect will be around USD 0.58 billion by 2030 with 10.7% rate of CAGR in the time span of forecasting. As the Addison's Disease market is determined by a set of driving forces, the composite of these elements solely determines its dynamics. Hypopituitarism is a rare but problems with the pituitary is a chronic endocrine disorder that is concerned with the insufficient production of hormones by the adrenal glands. Besides the rarity of the disease itself there is another key factor that plays a role in creating the problem – low awareness and late diagnosis that result in a greater difficulties with the disease management. Given its infrequent occurrence compared to common diseases, the demand of unusual treatment plans/drugs is not as much as other high-priority needs. Pharmaceutical industry engages the significant level of responsibility, investigating the ways to achieve the hormonal compensation in Addison's Disease to satisfy the specific demands of affected individuals. The market for treatment of Addison's disease experiences major changes as the result of innovation in medications that determine the development of such a competitive landscape among pharmaceutical companies, and all those companies are focused on the development of such effective and customized solutions in the field of management of Addison's disease.
Regulatory barriers could also shape the Adams Disease market. Strict laws and of the doctors certify the security and performance of the medications to manage the rare endocrine disorder called hyperparathyroidism. Meeting the prerequisites of regulatory guidelines is legal for drug companies at their attempt to bring new remedies to the market, as or new medicinesh are regarded as safe and efficient by healthcare professionals and patients after having to receive an approval from the regulatory authorities.
The economy perspective creates a major part of what’s the nature of Addison’s Disease market. The limited number of patients may pose economic problems in terms of economic viability for pharma companies. Research and development costs are expensive and small market size may make the drugs uncompetitive on the market. Besides, the arising economic burden, as the patient is supposed to cover healthcare costs and lose productivity due to chronic condition, may be an important factor determining the cost and availability of treatments within populations of different classes. While economic conditions, the trend of healthcare expenditure and different kinds of insurance have an influence on the growth of the addison's disease market that in turn aids in identification and obtaining of the prescribed treatments by the patients.
Patient education initiatives are absolutely of higher importance in that they affect the Addisnon's Disease field. Owing to the rarity of the endocrine disorder, consultations on giving awareness about Addison's Disease, its signs and therapeutic modalities are among the earliest possible diagnosis and management. Healthcare professionals and lobby groups do awareness campaigns to make sure that patients and the normal public get the right information and thus develops a proactive attitude towards managing Addison's disease and approaching appropriate medical treatment.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Growth Rate | 2020-2030:10.70% |
Addison’s Disease Market Highlights:
Addison’s Disease Market Overview:
Addison’s Disease Market Size was valued at USD 2.21 Billion in 2023. The Addison’s Disease industry is projected to grow from USD 2.34 Billion in 2024 to USD 5.35 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.84% during the forecast period (2024 - 2032). Addison's disease is a condition in which the body generates insufficient levels of certain hormones made by the adrenal glands. The adrenal glands generate too little cortisol and typically insufficient quantities of aldosterone in people with Addison's disease.
Adrenal insufficiency is another name for it. Addison's disease may afflict people of all ages and impact both men and women. The market is predicted to rise due to reasons such as the rising prevalence of Addison's disease, increased awareness of the condition, and rising healthcare spending. Lack of knowledge and difficulty to detect the condition in its early stages, on the other hand, may limit market growth throughout the projection period.
Segmentation
The Global Addison’s Disease Market has been segmented into diagnosis, treatment and end user.
The market, on the basis of diagnosis, has been segmented into laboratory tests and imaging tests. Laboratory tests have been further segmented into blood tests, ACTH stimulation tests, insulin-induced hypoglycemia test, and other tests. Blood tests are expected to hold the largest market share owing to their high effectiveness to diagnose the disease and preference among the physicians. ACTH stimulation test is expected to be the fastest growing market due to the low cost of the diagnosis method. Imaging tests have been segmented into chest radiography and CT scan.
The market, by treatment, has been segmented into oral corticosteroids and corticosteroids injections.
The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, and other end users.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Addison’s disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
- Pfizer Inc
- Boehringer Ingelheim International GmbH
- Shire
- Tocris Bioscience
- GlaxoSmithKline plc
- Merck KGaA
- Lupin Pharmaceuticals, Inc
- Abbott
- Amgen Limited & Amgen Ireland Limited
- Bayer AG
- Biogen
- Eli Lilly and Company
- Novartis AG
- Diurnal
- Switzer Life science Pvt. Ltd
Regional Market Summary
Global Addison’s Disease Market Share (%), by Region, 2017
Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the global Addison's disease market owing to a well-developed healthcare sector and the rising prevalence of the disease. According to a report published by the Centers Medicare and Medicaid Services in April 2018, National Healthcare Expenditure grew by 4.3% to USD 3.3 trillion in 2016 from the previous year.
Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to the increasing number of Addison’s disease cases and the developed healthcare infrastructure. According to the World Health Organization, Germany spent USD 5182 per capita on healthcare.
The Addison’s disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the increasing prevalence of Addison’s disease and growing awareness of the same. According to the World Bank Group, India spent 3.89% of its GDP on health in 2015.
The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.Recent Development
Lupin Ltd (Lupin) is a pharmaceutical company that produces and markets generic and branded pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Cardiovascular, diabetes etc are all part of the company's product range. Oral, ophthalmic, dermatological, and inhalation product research are key priorities for the organization. The company's operations are reported under a single segment, Pharmaceuticals. Formulations, active pharmaceutical ingredients (APIs), generic formulations, and biotechnology products are all part of Lupin's business.
In August 2015, Amgen, a biotechnology corporation located in the United States, launched its significantly enlarged production plant in Dun Laoghaire, Ireland. The $300 million expansion expanded manufacturing facilities to the existing factory, enhancing its capabilities and positioning it as a major hub for Amgen's global operations. The move was part of Amgen's long-term plan to manufacture all of its pharmaceuticals at the Dun Laoghaire facility, ensuring a steady supply of Amgen's medicines for severely sick patients across the world.
Global Addison’s Disease Market, by Diagnosis
- Laboratory Tests
- Blood Tests
- ACTH Stimulation Tests
- Insulin-Induced Hypoglycemia Test
- Other Tests
- Imaging Tests
- Chest Radiography
- CT Scan
Global Addison’s Disease Market, by Treatment
- Oral Corticosteroid
- Corticosteroid Injections
Global Addison’s Disease Market, by End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Other End Users
Global Addison’s Disease Market, by Region
- Americas
- North America
- US
- Canada
- South America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Global Addison’s Disease Market, by Key Players
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Shire
- Tocris Bioscience
- GlaxoSmithKline Plc
- Merck KGaA
- Lupin Pharmaceuticals, Inc.
- Abbott
- Amgen Limited & Amgen Ireland Limited
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
